Medivir
ISIN: SE0000273294 | Ticker: MVIR | LEI: 549300VWDGUX0WMJ1T79
Country: Sweden
Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients.
Medivir is developing MIV-818, a pro-drug designed to selectively treat liver cancer cells and to minimize side effects. It has the potential to become the first liver-targeted, orally administered drug for patients with HCC.
Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Birinapant, a SMAC mimetic, is exclusively outlicensed to IGM Biosciences (Nasdaq: IGMS) to be developed in combination with IGM-antibodies for the treatment of solid tumors.
1988
HeadquartersLunastigen 5, 2nd floor, 14122 Huddinge – Sweden
| Line item in (sek) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Assets | N/A | 191,462,000.00 | 335,825,000.00 | 234,197,000.00 |
| Noncurrent Assets | N/A | 112,531,000.00 | 109,909,000.00 | 111,153,000.00 |
| Property Plant And Equipment | N/A | 16,211,000.00 | 13,597,000.00 | 14,841,000.00 |
| Other Property Plant And Equipment | N/A | 92,000.00 | 0.00 | 340,000.00 |
| Intangible Assets Other Than Goodwill | N/A | 96,320,000.00 | 96,312,000.00 | 96,312,000.00 |
| Intangible Assets Under Development | N/A | 96,312,000.00 | 96,312,000.00 | 96,312,000.00 |
| Other Intangible Assets | N/A | 8,000.00 | 0.00 | 0.00 |
| Other Noncurrent Financial Assets | N/A | 0.00 | 0.00 | 0.00 |
| Current Assets | N/A | 78,931,000.00 | 225,917,000.00 | 123,044,000.00 |
| Current Trade Receivables | N/A | 15,000.00 | N/A | N/A |
| Other Current Receivables | N/A | 3,199,000.00 | 1,294,000.00 | 1,379,000.00 |
| Current Tax Assets Current | N/A | 778,000.00 | 1,446,000.00 | 1,446,000.00 |
| Cash and cash equivalents | 134,509,000.00 | 70,007,000.00 | 221,167,000.00 | 117,434,000.00 |
| Cash | N/A | 14,038,000.00 | 14,690,000.00 | 6,448,000.00 |
| Cash Equivalents | N/A | 55,969,000.00 | 206,477,000.00 | 110,986,000.00 |
| Equity And Liabilities | N/A | 191,462,000.00 | 335,825,000.00 | 234,197,000.00 |
| Equity | 184,456,000.00 | 141,905,000.00 | 281,146,000.00 | 192,789,000.00 |
| Issued Capital | N/A | 188,494,000.00 | 27,868,000.00 | 27,868,000.00 |
| Retained Earnings | N/A | -463,655,000.00 | -548,419,000.00 | -637,184,000.00 |
| Additional Paidin Capital | N/A | 420,804,000.00 | 804,944,000.00 | 805,349,000.00 |
| Noncurrent Liabilities | N/A | 14,888,000.00 | 12,964,000.00 | 13,399,000.00 |
| Current Liabilities | N/A | 34,670,000.00 | 41,716,000.00 | 28,009,000.00 |
| Trade And Other Current Payables To Trade Suppliers | N/A | 6,808,000.00 | 10,338,000.00 | 3,763,000.00 |
| Accruals Classified As Current | N/A | 25,414,000.00 | 29,171,000.00 | 20,673,000.00 |
| Other Current Payables | N/A | 848,000.00 | 1,153,000.00 | 1,460,000.00 |
| Line item in (sek) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue From Royalties | 13,948,000.00 | 25,538,000.00 | 4,408,000.00 |
| Employee Benefits Expense | 24,931,000.00 | 21,415,000.00 | 20,735,000.00 |
| Depreciation And Amortisation Expense | 4,430,000.00 | 2,595,000.00 | 2,571,000.00 |
| Other Expense By Nature | 52,932,000.00 | 73,277,000.00 | 69,078,000.00 |
| Profit Loss From Operating Activities | -42,900,000.00 | -62,118,000.00 | -87,354,000.00 |
| Finance Income | 827,000.00 | 490,000.00 | 8,000.00 |
| Finance Costs | 547,000.00 | 950,000.00 | 1,419,000.00 |
| Profit Loss Before Tax | -42,620,000.00 | -62,579,000.00 | -88,765,000.00 |
| Income Tax Expense Continuing Operations | N/A | 546,000.00 | N/A |
| Profit (loss) | -42,620,000.00 | -63,125,000.00 | -88,765,000.00 |
| Profit Loss Attributable To Owners Of Parent | -42,620,000.00 | -63,125,000.00 | -88,765,000.00 |
| Line item in (sek) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | N/A | -42,620,000.00 | -63,125,000.00 | -88,765,000.00 |
| Other Adjustments For Noncash Items | N/A | -13,937,000.00 | 2,622,000.00 | 2,571,000.00 |
| Cash Flows From Used In Operations | N/A | -56,557,000.00 | -59,957,000.00 | -86,194,000.00 |
| Income Taxes Paid Refund Classified As Operating Activities | N/A | -799,000.00 | 1,214,000.00 | N/A |
| Other Inflows Outflows Of Cash Classified As Operating Activities | N/A | 6,346,000.00 | N/A | N/A |
| Cash Flows From Used In Operating Activities | N/A | -58,053,000.00 | -48,734,000.00 | -101,820,000.00 |
| Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities | N/A | 1,706,000.00 | N/A | N/A |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 2,684,000.00 | 0.00 | 382,000.00 |
| Cash Flows From Used In Investing Activities | N/A | 5,368,000.00 | 0.00 | -382,000.00 |
| Proceeds From Issuing Shares | N/A | N/A | 222,763,000.00 | 0.00 |
| Proceeds From Issuing Other Equity Instruments | N/A | 595,000.00 | 752,000.00 | 404,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 12,713,000.00 | 2,475,000.00 | 1,940,000.00 |
| Cash Flows From Used In Financing Activities | N/A | -12,118,000.00 | 199,400,000.00 | -1,535,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | N/A | -64,803,000.00 | 150,666,000.00 | -103,737,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | 301,000.00 | 494,000.00 | 3,000.00 |
| Cash and cash equivalents | 134,509,000.00 | 70,007,000.00 | 221,167,000.00 | 117,434,000.00 |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 15.11.22 | Fredrik Öberg | Other | Buy | SEK 77,000.00 |
| 14.11.22 | Jens Anders Fredrik Lindberg | Other | Buy | SEK 192,500.00 |
| 14.11.22 | Magnus Christensen | Other | Buy | SEK 115,500.00 |
| 28.03.22 | Jens Anders Fredrik Lindberg | Other | Buy | SEK 122,850.00 |
| 25.03.22 | Jens Anders Fredrik Lindberg | Other | Buy | SEK 80,000.00 |
| 03.03.22 | Magnus Christensen | Other | Buy | SEK 46,800.00 |
| 23.12.21 | Malene Jensen | Other | Buy | SEK 25,650.00 |
| 13.12.21 | Malene Jensen | Other | Buy | SEK 109,500.00 |
| 13.12.21 | Malene Jensen | Other | Buy | SEK 85,500.00 |
| 13.05.21 | Fredrik Öberg | Other | Buy | SEK 97,500.00 |
SE0000273294
LEI549300VWDGUX0WMJ1T79
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.